A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15100 participants.
Also called NCT07000357
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 15,100 participants
- Sponsor
- Registry
-
NCT07000357 -
2025-520519-14
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Philippines, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07000357. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-04 (actual); primary completion 2029-10-26 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Acronym
- AZURE-Outcomes
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- AZD0780
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07000357- Content hash
7975b34a912c972437fbc74c49a01a8688abb8dc49e4d8d3d29f8d2bc5e2c3de